SynthesisBritish journal of clinical pharmacology2006
Pharmacokinetics of ribavirin in patients with hepatitis C virus.
Synthesis in British journal of clinical pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01289496 (Ribavirin Dose Optimization for the Treatment of Hepatitis C), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ribavirin Dose Optimization for the Treatment of Hepatitis C: A Pilot Study
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.British journal of clinical pharmacology · 2006Pooled it
- Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.The Journal of antimicrobial chemotherapy · 2015Trial
- Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.Antimicrobial agents and chemotherapy · 2013Trial
- Direct-Acting Antiviral Agents in Prevention of Maternal-Fetal Transmission of Hepatitis C Virus in Pregnancy.Pathogens (Basel, Switzerland) · 2024Review
- Utilization of Intravenous Ribavirin Among Reproductive Age Adults in 2010-2017: A Population-Based Study in the Yinzhou District, Ningbo City of China.Frontiers in public health · 2021Article
- The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment.Drug safety · 2017Article
- Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.British journal of clinical pharmacology · 2017Article
- Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies.The AAPS journal · 2016Article
- Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy.Hepatitis monthly · 2015Article
- Management of patients with hepatitis C infection and renal disease.World journal of hepatology · 2015Review
- Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial.Pharmacogenomics and personalized medicine · 2015Article
- Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.BMC infectious diseases · 2014Article
- Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.The AAPS journal · 2012Article
- A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.Journal of clinical and experimental hepatology · 2012Review
- A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.PLoS computational biology · 2012Article
- Antiviral drugs for viruses other than human immunodeficiency virus.Mayo Clinic proceedings · 2011Review
- The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C.Hepatitis monthly · 2011Article
- Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2).The Journal of pharmacology and experimental therapeutics · 2009Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimA population pharmacokinetic analysis was performed using plasma concentration data (n = 7025) from 380 patients to examine the relationship between ribavirin dose and its pharmacokinetics.
methodsRibavirin pharmacokinetics were described by a three-compartment model with sequential zero-order and a first-order absorption processes. Interoccasion variability and food effects were included.
resultsLean body weight (range 41-91 kg) was the only covariate with a clinically significant influence on ribavirin pharmacokinetics, affecting clearance (15.3-23.9 l h(-1)) and the volume of the larger peripheral compartment.
conclusionThe model provided a good description of the available data, confirmed by accurate estimates of parameter values and low residual variability (17%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.